儿童和青少年2019冠状病毒病的临床表现及流行病学意义

胡亚红; 姚开虎

doi:10.7499/j.issn.1008-8830.2205026

PDF(542 KB)

HTML

中国当代儿科杂志 ›› 2022, Vol. 24 ›› Issue (8) : 846-852. DOI: 10.7499/j.issn.1008-8830.2205026

疫情专栏

儿童和青少年2019冠状病毒病的临床表现及流行病学意义

胡亚红, 姚开虎

作者信息 +

Clinical characteristics and epidemiological significance of coronavirus disease 2019 in children and adolescents

HU Ya-Hong, YAO Kai-Hu

Author information +

文章历史 +

摘要

2019年底开始的2019冠状病毒病（coronavirus disease 2019，COVID-19）疫情在几个月内迅速蔓延全球，2020年3月世界卫生组织宣布为全球疫情。根据美国儿科学会的数据，自疫情暴发以来，已有近1 300万儿童确诊为COVID-19。总的来说，儿童和青少年COVID-19的症状比成人轻，病死率也较低。了解儿童和青少年中COVID-19的症状、传染性和传播模式对及时识别可疑患者和采取完善的管控措施具有重要意义。考虑到将来相当一段时间内，总会有一部分儿童尚不能接种疫苗，提高对儿童和青少年COVID-19的临床及流行病学意义认识就显得更重要。该文总结了儿童和青少年COVID-19临床表现的当前认识，分析其流行病学意义，为临床诊治、管理，以及幼儿园和学校等儿童聚集机构制订疫情防控策略提供参考。

Abstract

The epidemic of coronavirus disease 2019 (COVID-19) started in late December 2019, and spread rapidly throughout the world. In March 2020, the World Health Organization (WHO) declared global epidemic of COVID-19. According to the American Academy of Pediatrics, nearly 13 million children have been diagnosed with COVID-19 since the outbreak. In general, children and teens have milder symptoms and fewer deaths from COVID-19 than adults. Understanding the symptoms, infectivity, and transmission patterns of COVID-19 in children and adolescents is of great significance for timely identifying suspected patients and developing effective control measures. Considering that some children will not be vaccinated for quite some time in the future, it is more important to improve the understanding of the clinical and epidemiological significance of COVID-19 in children and adolescents. This article summarizes the current understanding of the clinical manifestations and epidemiological significance of COVID-19 in children and adolescents to provide a reference for clinical diagnosis and treatment and the formulation of epidemic prevention and control strategies in children's gathering institutions such as kindergartens and schools.

导出引用

胡亚红, 姚开虎. 儿童和青少年2019冠状病毒病的临床表现及流行病学意义[J]. 中国当代儿科杂志. 2022, 24(8): 846-852 https://doi.org/10.7499/j.issn.1008-8830.2205026

HU Ya-Hong, YAO Kai-Hu. Clinical characteristics and epidemiological significance of coronavirus disease 2019 in children and adolescents[J]. Chinese Journal of Contemporary Pediatrics. 2022, 24(8): 846-852 https://doi.org/10.7499/j.issn.1008-8830.2205026

参考文献

1 The American Academy of Pediatrics. Children and COVID-19: state-level data report[EB/OL]. [2022-04-20]. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/.
2 World Health Organization. COVID-19 disease in children and adolescents: scientific brief, 29 September 2021[EB/OL]. [2022-04-20]. https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1.
3 Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis[J]. Travel Med Infect Dis, 2020, 34: 101623. PMID: 32179124. PMCID: PMC7102608. DOI: 10.1016/j.tmaid.2020.101623.
4 Ray STJ, Abdel-Mannan O, Sa M, et al. Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study[J]. Lancet Child Adolesc Health, 2021, 5(9): 631-641. PMID: 34273304. PMCID: PMC8279959. DOI: 10.1016/S2352-4642(21)00193-0.
5 Lin JE, Asfour A, Sewell TB, et al. Neurological issues in children with COVID-19[J]. Neurosci Lett, 2021, 743: 135567. PMID: 33352286. PMCID: PMC7831718. DOI: 10.1016/j.neulet.2020.135567.
6 Xia W, Shao J, Guo Y, et al. Clinical and CT features in pediatric patients with COVID-19 infection: different points from adults[J]. Pediatr Pulmonol, 2020, 55(5): 1169-1174. PMID: 32134205. PMCID: PMC7168071. DOI: 10.1002/ppul.24718.
7 Brisca G, Mallamaci M, Tardini G, et al. SARS-CoV-2 infection may present as acute hepatitis in children[J]. Pediatr Infect Dis J, 2021, 40(5): e214-e215. PMID: 33591076. DOI: 10.1097/INF.0000000000003098.
8 Qiu C, Cui C, Hautefort C, et al. Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study[J]. Otolaryngol Head Neck Surg, 2020, 163(4): 714-721. PMID: 32539586. PMCID: PMC7298561. DOI: 10.1177/0194599820934376.
9 Mak PQ, Chung KS, Wong JS, et al. Anosmia and ageusia: not an uncommon presentation of COVID-19 infection in children and adolescents[J]. Pediatr Infect Dis J, 2020, 39(8): e199-e200. PMID: 32516281. DOI: 10.1097/INF.0000000000002718.
10 Marhaeni W, Wijaya AB, Kusumaningtyas P, et al. Thalassemic child presenting with anosmia due to COVID-19[J]. Indian J Pediatr, 2020, 87(9): 750. PMID: 32519260. PMCID: PMC7281692. DOI: 10.1007/s12098-020-03370-4.
11 Irfan O, Muttalib F, Tang K, et al. Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis[J]. Arch Dis Child, 2021, 106(5): 440-448. PMID: 33593743. PMCID: PMC8070630. DOI: 10.1136/archdischild-2020-321385.
12 Whittaker E, Bamford A, Kenny J, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2[J]. JAMA, 2020, 324(3): 259-269. PMID: 32511692. PMCID: PMC7281356. DOI: 10.1001/jama.2020.10369.
13 Feldstein LR, Tenforde MW, Friedman KG, et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19[J]. JAMA, 2021, 325(11): 1074-1087. PMID: 33625505. PMCID: PMC7905703. DOI: 10.1001/jama.2021.2091.
14 Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, et al. Cardiovascular impact of COVID-19 with a focus on children: a systematic review[J]. World J Clin Cases, 2020, 8(21): 5250-5283. PMID: 33269260. PMCID: PMC7674714. DOI: 10.12998/wjcc.v8.i21.5250.
15 Feldstein LR, Rose EB, Horwitz SM, et al. Multisystem inflammatory syndrome in U.S. children and adolescents[J]. N Engl J Med, 2020, 383(4): 334-346. PMID: 32598831. PMCID: PMC7346765. DOI: 10.1056/NEJMoa2021680.
16 Belay ED, Abrams J, Oster ME, et al. Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic[J]. JAMA Pediatr, 2021, 175(8): 837-845. PMID: 33821923. PMCID: PMC8025123. DOI: 10.1001/jamapediatrics.2021.0630.
17 Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study[J]. Lancet, 2020, 395(10239): 1771-1778. PMID: 32410760. PMCID: PMC7220177. DOI: 10.1016/S0140-6736(20)31103-X.
18 Centers for Disease Control and Prevention. Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States[EB/OL]. [2021-02-20]. https://stacks.cdc.gov/view/cdc/103708.
19 Centers for Disease Control and Prevention. COVID data tracker[EB/OL]. [2021-02-20]. https://covid.cdc.gov/covid-data-tracker/#datatracker-home.
20 Centers for Disease Control and Prevention. Health department-reported cases of multisystem inflammatory syndrome in children (MIS-C) in the United States[EB/OL]. [2021-08-21]. https://stacks.cdc.gov/view/cdc/108894.
21 Parcha V, Booker KS, Kalra R, et al. A retrospective cohort study of 12,306 pediatric COVID-19 patients in the United States[J]. Sci Rep, 2021, 11(1): 10231. PMID: 33986390. PMCID: PMC8119690. DOI: 10.1038/s41598-021-89553-1.
22 G?tzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study[J]. Lancet Child Adolesc Health, 2020, 4(9): 653-661. PMID: 32593339. PMCID: PMC7316447. DOI: 10.1016/S2352-4642(20)30177-2.
23 Sacco K, Castagnoli R, Vakkilainen S, et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19[J]. Nat Med, 2022, 28(5): 1050-1062. PMID: 35177862. PMCID: PMC9119950. DOI: 10.1038/s41591-022-01724-3.
24 Gale C, Quigley MA, Placzek A, et al. Characteristics and outcomes of neonatal SARS-CoV-2 infection in the UK: a prospective national cohort study using active surveillance[J]. Lancet Child Adolesc Health, 2021, 5(2): 113-121. PMID: 33181124. PMCID: PMC7818530. DOI: 10.1016/S2352-4642(20)30342-4.
25 Buonsenso D, Munblit D, De Rose C, et al. Preliminary evidence on long COVID in children[J]. Acta Paediatr, 2021, 110(7): 2208-2211. PMID: 33835507. PMCID: PMC8251440. DOI: 10.1111/apa.15870.
26 The Lancet. Understanding long COVID: a modern medical challenge[J]. Lancet, 2021, 398(10302): 725. PMID: 34454656. PMCID: PMC8389978. DOI: 10.1016/S0140-6736(21)01900-0.
27 Lu X, Zhang L, Du H, et al. SARS-CoV-2 infection in children[J]. N Engl J Med, 2020, 382(17): 1663-1665. PMID: 32187458. PMCID: PMC7121177. DOI: 10.1056/NEJMc2005073.
28 Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus[J]. Nature, 2003, 426(6965): 450-454. PMID: 14647384. PMCID: PMC7095016. DOI: 10.1038/nature02145.
29 Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry[J]. J Virol, 2020, 94(5): e02015-19. PMID: 31826992. PMCID: PMC7022351. DOI: 10.1128/JVI.02015-19.
30 Korean Society of Infectious Diseases and Korea Centers for Disease Control and Prevention. Analysis on 54 mortality cases of coronavirus disease 2019 in the republic of Korea from January 19 to March 10, 2020[J]. J Korean Med Sci, 2020, 35(12): e132. PMID: 32233161. PMCID: PMC7105509. DOI: 10.3346/jkms.2020.35.e132.
31 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China[J]. Pediatrics, 2020, 145(6): e20200702. PMID: 32179660. DOI: 10.1542/peds.2020-0702.
32 Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J]. Science, 2020, 367(6483): 1260-1263. PMID: 32075877. PMCID: PMC7164637. DOI: 10.1126/science.abb2507.
33 Felsenstein S, Hedrich CM. COVID-19 in children and young people[J]. Lancet Rheumatol, 2020, 2(9): e514-e516. PMID: 32838308. PMCID: PMC7324116. DOI: 10.1016/S2665-9913(20)30212-5.
34 Tosif S, Neeland MR, Sutton P, et al. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19[J]. Nat Commun, 2020, 11(1): 5703. PMID: 33177504. PMCID: PMC7658256. DOI: 10.1038/s41467-020-19545-8.
35 Loske J, R?hmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children[J]. Nat Biotechnol, 2022, 40(3): 319-324. PMID: 34408314. DOI: 10.1038/s41587-021-01037-9.
36 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China[J]. Pediatrics, 2020, 145(6): e20200702. PMID: 32179660. DOI: 10.1542/peds.2020-0702.
37 Siegel DA, Reses HE, Cool AJ, et al. Trends in COVID-19 cases, emergency department visits, and hospital admissions among children and adolescents aged 0-17 years—United States, August 2020-August 2021[J]. MMWR Morb Mortal Wkly Rep, 2021, 70(36): 1249-1254. PMID: 34499628. PMCID: PMC8437056. DOI: 10.15585/mmwr.mm7036e1.
38 World Health Organization. Tracking SARS-CoV-2 variants[EB/OL]. (2021-12-06)[2021-12-10]. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants.
39 Centers for Disease Control and Prevention. Omicron variant: what you need to know[EB/OL]. [2021-12-24]. https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html.
40 Wang L, Berger NA, Kaelber DC, et al. Comparison of outcomes from COVID infection in pediatric and adult patients before and after the emergence of Omicron[J]. medRxiv[Preprint]. (2022-01-02)[2022-04-28]. PMID: 35018384. PMCID: PMC8750707. DOI: 10.1101/2021.12.30.21268495.
41 Marks KJ, Whitaker M, Agathis NT, et al. Hospitalization of infants and children aged 0-4 years with laboratory-confirmed COVID-19—COVID-NET, 14 states, March 2020-February 2022[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(11): 429-436. PMID: 35298458. PMCID: PMC8942304. DOI: 10.15585/mmwr.mm7111e2.
42 Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study[J]. Lancet, 2022, 399(10332): 1303-1312. PMID: 35305296. PMCID: PMC8926413. DOI: 10.1016/S0140-6736(22)00462-7.
43 Cheung PH, Chan CP, Jin DY. Lessons learned from the fifth wave of COVID-19 in Hong Kong in early 2022[J]. Emerg Microbes Infect, 2022, 11(1): 1072-1078. PMID: 35348429. PMCID: PMC9004509. DOI: 10.1080/22221751.2022.2060137.
44 Zhang W, Du RH, Li B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes[J]. Emerg Microbes Infect, 2020, 9(1): 386-389. PMID: 32065057. PMCID: PMC7048229. DOI: 10.1080/22221751.2020.1729071.
45 Bullard J, Funk D, Dust K, et al. Infectivity of severe acute respiratory syndrome coronavirus 2 in children compared with adults[J]. CMAJ, 2021, 193(17): E601-E606. PMID: 33837039. PMCID: PMC8101972. DOI: 10.1503/cmaj.210263.
46 Szablewski CM, Chang KT, Brown MM, et al. SARS-CoV-2 transmission and infection among attendees of an overnight camp—Georgia, June 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(31): 1023-1025. PMID: 32759921. PMCID: PMC7454898. DOI: 10.15585/mmwr.mm6931e1.
47 Laxminarayan R, Wahl B, Dudala SR, et al. Epidemiology and transmission dynamics of COVID-19 in two Indian states[J]. Science, 2020, 370(6517): 691-697. PMID: 33154136. PMCID: PMC7857399. DOI: 10.1126/science.abd7672.
48 Forbes H, Morton CE, Bacon S, et al. Association between living with children and outcomes from covid-19: OpenSAFELY cohort study of 12 million adults in England[J]. BMJ, 2021, 372: n628. PMID: 33737413. PMCID: PMC7970340. DOI: 10.1136/bmj.n628.
49 Mossong J, Mombaerts L, Veiber L, et al. SARS-CoV-2 transmission in educational settings during an early summer epidemic wave in Luxembourg, 2020[J]. BMC Infect Dis, 2021, 21(1): 417. PMID: 33947340. PMCID: PMC8093902. DOI: 10.1186/s12879-021-06089-5.